|
![]() |
|
|
Glipizide: profile and news
Pfizer's Exubera(R): A Unique Background Perspective Jan 27, 2006 Preserving Competition, FTC Requires Divestitures Before Allowing ... Jan 23, 2006 Generic Version of Metaglip Approved Dec 7, 2005 FDA Approvals: Avelox, Avandaryl, Trileptal Dec 1, 2005 First-Time Generic Approvals: Metaglip, Zofran ODT, Floxin Otic Nov 22, 2005 Obesity is part of the sentence for prisoners Nov 12, 2005 Obesity is part of the sentence for prisoners Nov 12, 2005 Utah Prisoners Gain Weight At 3,000 Calories A Day Nov 13, 2005 Endocrinology & Metabolism News, September 2005 Oct 3, 2005 Sitagliptin, a new investigational treatment for type 2 diabetes ... Sep 14, 2005 Medicare sign-up deadline is looming Sep 16, 2005 Sitagliptin, Under Investigation For Type 2 Diabetes Sep 15, 2005 Many meds don't mix with the sun Sep 21, 2005 Endocrinology & Metabolism News, September 2005 Sep 7, 2005 Supplement of the Month - Cinnamon Sep 6, 2005 A TRUSS CAN BE A TEMPORARY FIX FOR A HERNIA Jul 23, 2005 Ask the internist: Variety of medications can help with diabetes ... Jul 19, 2005 Sitagliptin, an investigational treatment for type 2 diabetes Jun 14, 2005 Sitagliptin (MK-0431) for Type 2 Diabetes shows promise in Phase ... Jun 11, 2005 Top 10 Things to Know About Diabetes Pills Jul 4, 2005 Sitagliptin, an investigational treatment for type 2 diabetes Jun 14, 2005 Sitagliptin (MK-0431) for Type 2 Diabetes shows promise in Phase ... Jun 12, 2005 Hello, Byetta Jun 2, 2005 State investigates death at East Bay nursing home Apr 19, 2005 Daily drug regimen of Alice and Ken Heckman Apr 16, 2005 Paws to Consider Apr 19, 2005 Indian bulk drug suppliers lose pricing appeal Apr 11, 2005 Reminder: Keep medicines away from children Apr 5, 2005 Hospital fined $50,000 for error Nurse's mistake with diabetes ... Mar 2, 2005 Santa Rosa Hospital Fined In Patient's Death Mar 3, 2005 Alterations in net glucose uptake and in the pancreatic B-cell ... Feb 25, 2005 BCBSNC Launches New Prescription Drug Savings Initiative Feb 17, 2005 Epidural Hematoma Unrelated to Combined Spinal-Epidural Anesthesia ... Feb 22, 2005 Other information Indication For the treatment of hyperglycemia in Non-insulin-dependent diabetes mellitus (NIDDM) Pharmacology Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. Mechanism Of Action Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Drug Category Hypoglycemic Agents; ATC:A10BB07 Brand Names/Synonyms AC-120; Aldiab; Apamid; CHEMBANK72; Digrin; Dipazide; G117; Glibenese; Glibetin; Glican; Glide; Glidiab; Glipid; Glipizida [Inn-Spanish]; Glipizide; Glipizide Extended-Release Tablets; Glipizide [Usan:Ban:Inn]; Glipizidum [Inn-Latin]; Gluco-Rite; Glucolip; Glucotrol; Glucotrol Xl; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; K 4024; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Sucrazide; TK 1320 Dosage Forms IR oral tablets and ER oral tablets Absorption uniform, rapid, and essentially complete Interactions -->Interactions for Glipizide: Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control. In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81). Chemical IUPAC Name N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide Chemical Formula C22H28N4O4S Half Life 2-4 hours Drug Type Approved Drug # Accession No APRD00436 CAS Registry Number 29094-61-9 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |